[go: up one dir, main page]

MX2015017341A - Anticuerpos anti-factor del complemento c1q y uso de los mismos. - Google Patents

Anticuerpos anti-factor del complemento c1q y uso de los mismos.

Info

Publication number
MX2015017341A
MX2015017341A MX2015017341A MX2015017341A MX2015017341A MX 2015017341 A MX2015017341 A MX 2015017341A MX 2015017341 A MX2015017341 A MX 2015017341A MX 2015017341 A MX2015017341 A MX 2015017341A MX 2015017341 A MX2015017341 A MX 2015017341A
Authority
MX
Mexico
Prior art keywords
antibodies
complement factor
complement
factor
antic1q
Prior art date
Application number
MX2015017341A
Other languages
English (en)
Other versions
MX375500B (es
Inventor
Arnon Rosenthal
Michael Leviten
Original Assignee
Anexxon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anexxon Inc filed Critical Anexxon Inc
Publication of MX2015017341A publication Critical patent/MX2015017341A/es
Publication of MX375500B publication Critical patent/MX375500B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)

Abstract

La presente invención proporciona anticuerpos antiC1Q y métodos de uso de los mismos.
MX2015017341A 2013-07-09 2014-07-09 Anticuerpos anti-factor del complemento c1q y uso de los mismos. MX375500B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361844369P 2013-07-09 2013-07-09
US201361871813P 2013-08-29 2013-08-29
PCT/US2014/046042 WO2015006504A1 (en) 2013-07-09 2014-07-09 Anti-complement factor c1q antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2015017341A true MX2015017341A (es) 2016-07-06
MX375500B MX375500B (es) 2025-03-06

Family

ID=52280583

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017341A MX375500B (es) 2013-07-09 2014-07-09 Anticuerpos anti-factor del complemento c1q y uso de los mismos.
MX2020010141A MX2020010141A (es) 2013-07-09 2015-12-15 Anticuerpos anti-factor del complemento c1q y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010141A MX2020010141A (es) 2013-07-09 2015-12-15 Anticuerpos anti-factor del complemento c1q y uso de los mismos.

Country Status (23)

Country Link
US (7) US20160159890A1 (es)
EP (3) EP3019240B1 (es)
JP (2) JP6462680B2 (es)
KR (1) KR102321320B1 (es)
CN (1) CN105682740B (es)
AU (1) AU2014287221C1 (es)
BR (1) BR112016000106B1 (es)
CA (1) CA2916521C (es)
DK (1) DK3019240T3 (es)
EA (1) EA037325B1 (es)
ES (1) ES2978917T3 (es)
FI (1) FI3019240T3 (es)
HU (1) HUE066722T2 (es)
IL (1) IL243506B (es)
MX (2) MX375500B (es)
MY (1) MY175896A (es)
NZ (1) NZ715455A (es)
PL (1) PL3019240T3 (es)
PT (1) PT3019240T (es)
SG (3) SG11201510316UA (es)
SI (1) SI3019240T1 (es)
WO (2) WO2015006504A1 (es)
ZA (1) ZA201600157B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
CA3124553A1 (en) 2012-10-25 2014-05-01 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2014186622A2 (en) * 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
EA037325B1 (ru) 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
SG11201703667SA (en) * 2014-11-05 2017-06-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
CA2981851A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
IL296130A (en) * 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and their uses
JP2019514994A (ja) * 2016-05-09 2019-06-06 アネクソン，インコーポレーテッド 脊髄性筋萎縮症を治療するための組成物及び方法
CA3030872A1 (en) * 2016-07-19 2018-01-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
CN109689682B (zh) 2016-09-19 2022-11-29 豪夫迈·罗氏有限公司 基于补体因子的亲和层析
WO2018071676A1 (en) 2016-10-12 2018-04-19 Bioverativ Usa Inc. Anti-c1s antibodies and methods of use thereof
CN106699883B (zh) * 2016-12-19 2020-08-07 中国兽医药品监察所 豚鼠补体C1q-B单克隆抗体60G4的制备与应用
CN106822863A (zh) * 2017-01-04 2017-06-13 国家纳米科学中心 多肽‑抗体免疫偶联物及其制备方法
CN109843927B (zh) * 2017-03-06 2022-06-21 江苏恒瑞医药股份有限公司 抗b7-h3抗体、其抗原结合片段及其医药用途
AU2018341685A1 (en) * 2017-09-29 2020-04-02 Regeneron Pharmaceuticals, Inc. Non-human animals expressing humanized C1q complex
CN111556895B (zh) 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
WO2019137922A1 (en) * 2018-01-09 2019-07-18 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
WO2019238674A1 (en) 2018-06-11 2019-12-19 Aarhus Universitet Single domain antibodies for complement regulation
MX2019012869A (es) 2018-07-13 2020-01-23 Alector Llc Anticuerpos anti-sortilina y metodos para su uso.
WO2020072996A1 (en) 2018-10-05 2020-04-09 Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease
US20200140533A1 (en) * 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury
BR112021021689A2 (pt) 2019-05-15 2022-03-22 Chugai Pharmaceutical Co Ltd Molécula de ligação a antígeno, composição farmacêutica, e método
CN114829604B (zh) * 2019-10-16 2024-12-06 中外制药株式会社 抗体、药物组合物和方法
CA3157873A1 (en) * 2019-10-17 2021-04-22 Annexon, Inc. Compositions and methods for treating blood disorders
WO2021202807A1 (en) 2020-03-31 2021-10-07 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Proteomic screening for lysosomal storage diseases
EP4126939A4 (en) 2020-04-02 2024-08-21 Seattle Children's Hospital d/b/a Seattle Children's Research Institute ANTIBODIES THAT BIND SPECIFICALLY TO PEPTIDES ASSOCIATED WITH PRIMARY IMMUNODEFICIENCIES: WISKOTT-ALDRICH SYNDROME AND X-LINKED AGAMMAGLOBULINEMIA
CN115996752B (zh) * 2020-05-05 2025-04-01 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 用于治疗癫痫的组合物和方法
US20230175065A1 (en) 2020-05-08 2023-06-08 President And Fellows Of Harvard College Methods for treating inflammatory and autoimmune disorders
WO2021250323A1 (en) * 2020-06-09 2021-12-16 Helsingin Yliopisto Anti-cox-2 autoantibody as a diagnostic marker, and methods, kits and uses related thereto
PH12023550153A1 (en) * 2020-07-20 2024-03-18 Annexon Inc Inhibitors of complement factors and uses thereof
CA3195798A1 (en) * 2020-10-16 2022-04-21 Ted Yednock Compositions and methods for treating blood disorders
MX2023006591A (es) * 2020-12-04 2023-08-11 Annexon Inc Composiciones y metodos para el tratamiento de enfermedades oculares.
GB202113673D0 (en) * 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
EP4419144A4 (en) * 2021-10-21 2026-01-14 Annexon Inc COMPOSITIONS AND METHODS OF TREATMENT FOR MUSCULAR DYSTROPHY
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
GB2629959A (en) * 2021-12-29 2024-11-13 Curateq Biologics Private Ltd C1Q binding assay
KR20240126863A (ko) * 2021-12-30 2024-08-21 애넥슨, 인코포레이티드 헌팅턴병 치료용 조성물 및 방법
EP4463462A4 (en) 2022-01-14 2025-06-25 Annexon, Inc. COMPLEMENT FACTOR INHIBITORS AND RELATED USES
IL319755A (en) * 2022-10-07 2025-05-01 Annexon Inc Anti-C1Q antibody formulations
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
EP4670793A1 (en) * 2024-06-24 2025-12-31 Montis Biosciences BV C1Q ANTIGEN BINDING MOLECULES
CN119326377B (zh) * 2024-10-15 2025-07-22 复旦大学 一种基于影像的认知水平评估方法
CN120685919A (zh) * 2025-08-22 2025-09-23 中国科学院长春应用化学研究所 一种C1q补体蛋白在制备检测Aβ42蛋白的元件中的应用、一种检测Aβ42蛋白的芯片及其应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4595654A (en) * 1983-11-07 1986-06-17 Immunomedics Inc. Method for detecting immune complexes in serum
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
CA1338518C (en) 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US20020058311A1 (en) 1995-06-13 2002-05-16 Browne Michael Jospeh Chimeric leptin fused to immunoglobulin domain and use
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
ATE267257T1 (de) * 1996-11-27 2004-06-15 Genentech Inc Humanisierte anti-koerper gegen cd11a
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CA2301660A1 (en) * 1997-08-26 1999-03-04 Zymogenetics, Inc. Adipocyte-specific protein homologs
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030170781A1 (en) * 1999-07-01 2003-09-11 Zymogenetics, Inc. Secreted protein zacrp4
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6781029B2 (en) 2000-07-13 2004-08-24 University Of South Florida Transgenic animal and methods
US6872559B2 (en) 2000-10-26 2005-03-29 Wisconsin Alumni Research Foundation E. coli O157:H7 C1 esterase inhibitor-binding protein and methods of use
MXPA03007323A (es) 2001-02-19 2003-12-12 Merck Patent Gmbh Proteinas artificiales con inmunogenicidad reducida.
EP1583947A2 (en) 2001-11-07 2005-10-12 Human Genome Sciences, Inc. 41 human secreted proteins
US20040248156A1 (en) * 2001-12-03 2004-12-09 Tianhua Hu Methods and materials relating to novel C1q domain-containing polypeptides and polynucleotides
US20050214786A1 (en) 2002-02-22 2005-09-29 Human Genome Sciences, Inc. 26 human secreted proteins
WO2004042072A2 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
DK1628530T3 (da) 2003-05-15 2012-07-23 Genentech Inc Fremgangsmåder og sammensætninger til forebyggelse og behandling af sepsis
WO2005002513A2 (en) * 2003-06-16 2005-01-13 The Brigham And Women's Hospital, Inc. C1q complement inhibitors and methods of use thereof
WO2005002512A2 (en) 2003-06-19 2005-01-13 University Of Rochester Immunotherapeutic vaccine strategy
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1718677B1 (en) 2003-12-19 2012-04-18 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
CN101001872A (zh) 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
US7544855B2 (en) 2004-04-23 2009-06-09 Buck Institute Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2006063150A2 (en) 2004-12-08 2006-06-15 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
EP1838735A2 (en) 2004-12-31 2007-10-03 Genentech, Inc. Polypeptides that bind br3 and uses thereof
CN101073584B (zh) * 2005-10-14 2012-10-10 全面技术公司 改变细胞功能的方法和组合物
US9480658B2 (en) 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US8148330B2 (en) 2005-12-09 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
NO347079B1 (no) * 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Forbedrede protofibrilselektive antistoffer og anvendelse derav
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
MX2009002426A (es) 2006-09-05 2009-03-20 Alexion Pharma Inc Metodos y composiciones para el tratamiento de neuropatias mediadas por anticuerpo.
CN101657097A (zh) 2007-03-01 2010-02-24 先进视觉疗法公司 以炎症为特征的疾病的治疗
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101855242B (zh) 2007-09-14 2014-07-30 阿迪马布有限责任公司 合理设计的合成抗体文库及其用途
AR069610A1 (es) 2007-12-11 2010-02-03 Glaxo Group Ltd Proteinas de union a antigenos que se unen al peptido beta-amiloide
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CA2740192C (en) 2008-12-01 2019-12-31 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detection of complement fixing antibodies
US8922441B2 (en) 2009-04-28 2014-12-30 Panasonic Corporation Receiver
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
WO2012067267A1 (en) 2010-11-18 2012-05-24 Takahiro Ochi TESTING METHOD USING ANTI-C1q MONOCLONAL ANTIBODY
HUE063461T2 (hu) 2011-05-27 2024-01-28 Glaxo Group Ltd BCMA (CD269/TNFRSF17)-kötõ fehérjék
US9127061B2 (en) 2011-06-24 2015-09-08 Perseus Proteomics Inc. Anti-human P-cadherin (CDH3) recombinant antibody
DK2794905T3 (da) 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
WO2013166604A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Single-arm monovalent antibody constructs and uses thereof
BR112014031522A2 (pt) 2012-06-18 2017-08-01 Omeros Corp métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento
CA3124553A1 (en) * 2012-10-25 2014-05-01 Bioverativ Usa Inc. Anti-complement c1s antibodies and uses thereof
CN116063483A (zh) 2012-11-02 2023-05-05 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
WO2014186622A2 (en) 2013-05-15 2014-11-20 Annexon, Inc. Methods of treatment for guillain-barre syndrome
EA037325B1 (ru) 2013-07-09 2021-03-12 Аннексон, Инк. Антитела против фактора комплемента c1q и их применения
SG11201703667SA (en) 2014-11-05 2017-06-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
IL296130A (en) 2015-11-24 2022-11-01 Annexon Inc Anti-complement factor c1q fab fragments and their uses
JP2019514994A (ja) 2016-05-09 2019-06-06 アネクソン，インコーポレーテッド 脊髄性筋萎縮症を治療するための組成物及び方法
CA3030872A1 (en) 2016-07-19 2018-01-25 Annexon, Inc. Compositions and methods for treating frontotemporal dementia
US20200140533A1 (en) 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury
CA3157873A1 (en) 2019-10-17 2021-04-22 Annexon, Inc. Compositions and methods for treating blood disorders
CN113185611A (zh) 2019-12-05 2021-07-30 启愈生物技术(上海)有限公司 含有肿瘤相关抗原taa抗体的三功能融合蛋白及其应用
CN115996752B (zh) 2020-05-05 2025-04-01 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 用于治疗癫痫的组合物和方法
JP2023537553A (ja) 2020-08-14 2023-09-04 中外製薬株式会社 ワンアームド抗原結合分子およびその使用
CA3195798A1 (en) 2020-10-16 2022-04-21 Ted Yednock Compositions and methods for treating blood disorders
MX2023006591A (es) 2020-12-04 2023-08-11 Annexon Inc Composiciones y metodos para el tratamiento de enfermedades oculares.
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof

Also Published As

Publication number Publication date
MX2020010141A (es) 2020-10-20
HK1225678A1 (zh) 2017-09-15
US20200239557A1 (en) 2020-07-30
CA2916521A1 (en) 2015-01-15
NZ715455A (en) 2021-12-24
US20170334976A1 (en) 2017-11-23
JP2019071889A (ja) 2019-05-16
US20160159890A1 (en) 2016-06-09
EP3019523A4 (en) 2016-12-28
IL243506B (en) 2021-07-29
JP2016526393A (ja) 2016-09-05
US10927167B2 (en) 2021-02-23
WO2015006507A1 (en) 2015-01-15
EP3019240A1 (en) 2016-05-18
ZA201600157B (en) 2025-10-29
PT3019240T (pt) 2024-06-06
KR102321320B1 (ko) 2021-11-03
MY175896A (en) 2020-07-14
BR112016000106B1 (pt) 2023-11-21
US20240083987A1 (en) 2024-03-14
US20210277096A1 (en) 2021-09-09
EP3019523A1 (en) 2016-05-18
EA037325B1 (ru) 2021-03-12
MX375500B (es) 2025-03-06
US12534522B2 (en) 2026-01-27
DK3019240T3 (da) 2024-06-03
IL243506A0 (en) 2016-02-29
SG11201510316UA (en) 2016-01-28
CN105682740A (zh) 2016-06-15
AU2014287221B2 (en) 2019-09-12
US10590190B2 (en) 2020-03-17
US9708394B2 (en) 2017-07-18
AU2014287221A1 (en) 2016-01-21
FI3019240T3 (fi) 2024-05-30
JP6462680B2 (ja) 2019-01-30
SI3019240T1 (sl) 2024-07-31
EP4252769A3 (en) 2023-11-29
SG10201710758PA (en) 2018-02-27
EP3019240A4 (en) 2017-01-04
CN105682740B (zh) 2021-06-11
PL3019240T3 (pl) 2024-08-19
EP3019240B1 (en) 2024-03-13
EA201690182A1 (ru) 2016-10-31
HUE066722T2 (hu) 2024-09-28
KR20160058752A (ko) 2016-05-25
AU2014287221C1 (en) 2020-03-05
US11649279B2 (en) 2023-05-16
WO2015006504A1 (en) 2015-01-15
ES2978917T3 (es) 2024-09-23
CA2916521C (en) 2023-03-07
BR112016000106A2 (pt) 2017-12-12
US10227398B2 (en) 2019-03-12
EP4252769A2 (en) 2023-10-04
SG10202008809RA (en) 2020-10-29
US20160368973A1 (en) 2016-12-22
JP6653009B2 (ja) 2020-02-26
US20190211084A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
MX2015017341A (es) Anticuerpos anti-factor del complemento c1q y uso de los mismos.
MX2016005631A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
CL2016001102A1 (es) Anticuerpos anti-claudina novedosos y métodos de uso.
MX2022005202A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
BR112015032224A2 (pt) anticorpos anti-fcrh5
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
CL2015003406A1 (es) Anticuerpos receptores de antitransferina y métodos de uso campo de la invención
MX388018B (es) Anticuerpos anti-pd1 y métodos de uso.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
PT2956175T (pt) Recetor de antigénio quimérico e métodos de utilização do mesmo
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
UY34876A (es) Anticuerpos anti-egfr y usos de los mismos
MX390891B (es) ANTICUERPOS ANTI-HtrA1 Y MÉTODOS DE USO.
ECSP13012786A (es) Anticuerpos anti-pcsk9 y métodos de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso

Legal Events

Date Code Title Description
FG Grant or registration